ABBV: EC Approves SKYRIZI
AbbVie's SKYRIZI is approved by the European Commission for children and adolescents with moderate to severe plaque psoriasis
AbbVie Says European Commission Approves SKYRIZI For Children And Adolescents Six Years And Older With Moderate To Severe Plaque Psoriasis